hydroxychloroquine has been researched along with Fatigue Syndrome, Chronic in 2 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Fatigue Syndrome, Chronic: A syndrome characterized by persistent or recurrent fatigue, diffuse musculoskeletal pain, sleep disturbances, and subjective cognitive impairment of 6 months duration or longer. Symptoms are not caused by ongoing exertion; are not relieved by rest; and result in a substantial reduction of previous levels of occupational, educational, social, or personal activities. Minor alterations of immune, neuroendocrine, and autonomic function may be associated with this syndrome. There is also considerable overlap between this condition and FIBROMYALGIA. (From Semin Neurol 1998;18(2):237-42; Ann Intern Med 1994 Dec 15;121(12): 953-9)
Excerpt | Relevance | Reference |
---|---|---|
"The diagnosis is mainly serological." | 2.45 | [Q fever: current diagnosis and treatment options]. ( Lepidi, H; Million, M; Raoult, D, 2009) |
"Moreover, PTSD in patients with COVID-19 is not associated with the increased risk of CFS." | 1.62 | Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19. ( Aalipour, MA; Darazam, IA; Ghorbani, F; Pakdaman, H; Ramezani, M; Sagharichi, M; Simani, L, 2021) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Simani, L | 1 |
Ramezani, M | 1 |
Darazam, IA | 1 |
Sagharichi, M | 1 |
Aalipour, MA | 1 |
Ghorbani, F | 1 |
Pakdaman, H | 1 |
Million, M | 1 |
Lepidi, H | 1 |
Raoult, D | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Efficacy and Security of the Magnesium and Vitamin D Combination as Adjuvant Treatment of Post-COVID Syndrome. A Randomised Double-blind Clinical Trial[NCT05630339] | 150 participants (Actual) | Interventional | 2022-01-30 | Completed | |||
Neuropsychological Sequelae as a Risk Factor for Long COVID-19 Fatigue[NCT05323318] | 200 participants (Anticipated) | Observational | 2022-04-01 | Recruiting | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 review available for hydroxychloroquine and Fatigue Syndrome, Chronic
Article | Year |
---|---|
[Q fever: current diagnosis and treatment options].
Topics: Animals; Coxiella burnetii; Diagnosis, Differential; Doxycycline; Fatigue Syndrome, Chronic; Humans; | 2009 |
1 other study available for hydroxychloroquine and Fatigue Syndrome, Chronic
Article | Year |
---|---|
Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19.
Topics: Adult; Aged; Antiviral Agents; Cough; COVID-19; COVID-19 Drug Treatment; Dementia; Drug Combinations | 2021 |
Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19.
Topics: Adult; Aged; Antiviral Agents; Cough; COVID-19; COVID-19 Drug Treatment; Dementia; Drug Combinations | 2021 |
Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19.
Topics: Adult; Aged; Antiviral Agents; Cough; COVID-19; COVID-19 Drug Treatment; Dementia; Drug Combinations | 2021 |
Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19.
Topics: Adult; Aged; Antiviral Agents; Cough; COVID-19; COVID-19 Drug Treatment; Dementia; Drug Combinations | 2021 |